Mesoblast (NASDAQ:MESO) reported robust financial results for the first quarter of 2026, driven by the successful commercial trajectory of Ryoncil (remestemcel-L).
The company recorded net revenues of $30.3 million for the quarter ended March 31, 2026, with gross sales reaching $35.3 million.
The performance puts Ryoncil on pace to hit $100 million in sales during its inaugural launch year, underscoring strong market adoption for the first FDA-approved mesenchymal stromal cell (MSC) therapy.
The company also demonstrated improved capital discipline, with net operating cash spend narrowing to $4.1 million for the quarter.
This fiscal efficiency was supported by $34.6 million in receipts, leaving Mesoblast with a cash position of $122 million as of March 31.
Management noted that the reduction in cash burn provides a longer runway to fund a rapidly expanding clinical pipeline.
Operationally, Mesoblast achieved several high-impact milestones during the quarter.
The company completed patient enrollment for its pivotal Phase 3 trial of rexlemestrocel-L, targeting chronic low back pain (CLBP), a condition with potential blockbuster status in the U.S.
The FDA also granted Investigational New Drug (IND) clearance for a registrational trial of Ryoncil in Duchenne Muscular Dystrophy (DMD), allowing the company to skip mid-stage trials and move directly toward approval for the rare pediatric disease.
Elsewhere, a new label-extension trial commenced for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in adults, while the company secured an exclusive worldwide license for chimeric antigen receptor (CAR) technology from a Mayo Clinic spinout to engineer precision-enhanced MSCs.